ticlopidine has been researched along with Diabetic Angiopathies in 46 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 9.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 9.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events." | 9.14 | Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 9.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "The Ticlopidine Microangiopathy of Diabetes study (TIMAD), a randomized, double-masked, placebo-controlled trial, assessed the effect of this antiplatelet agent (ticlopidine hydrochloride) in reducing the progression of nonproliferative diabetic retinopathy in 435 patients followed up for 3 years." | 9.06 | Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. ( , 1990) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 6.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 6.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| "This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy." | 5.17 | Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013) |
| "In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level." | 5.16 | Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012) |
| "ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events." | 5.14 | Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010) |
| "We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)." | 5.13 | Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008) |
| "The Ticlopidine Microangiopathy of Diabetes study (TIMAD), a randomized, double-masked, placebo-controlled trial, assessed the effect of this antiplatelet agent (ticlopidine hydrochloride) in reducing the progression of nonproliferative diabetic retinopathy in 435 patients followed up for 3 years." | 5.06 | Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group. ( , 1990) |
| " Laboratory and clinical data have convincingly shown the benefit of P2Y12 inhibition combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous coronary intervention (PCI)." | 4.90 | p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. ( Alexopoulos, D, 2014) |
| "We sought to assess the impact of renal function on platelet reactivity in patients with diabetes mellitus (DM) and coronary artery disease on aspirin and clopidogrel therapy." | 3.76 | Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010) |
| " The present study attempts to study the pharmacodynamic interactions of P." | 2.79 | Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus. ( Fatima, N; Muralidhar, N; Pingali, U, 2014) |
| " The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM." | 2.76 | A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011) |
| "Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade." | 2.73 | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008) |
| " Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)." | 2.48 | Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. ( Angiolillo, DJ; Ferreiro, JL, 2012) |
| "Diabetes mellitus is commonly associated with both microvascular and macrovascular complications (coronary artery disease, cerebrovascular events, severe peripheral vascular disease, nephropathy and retinopathy)." | 2.45 | Diabetes, vascular complications and antiplatelet therapy: open problems. ( Cerbone, AM; Coppola, A; Di Minno, G; Macarone-Palmieri, N; Rivellese, AA; Saldalamacchia, G, 2009) |
| "We present a patient with type 2 diabetes mellitus, arterial hypertension and hyperlipidaemia, who had simultaneous oculomotor and trochlear nerve palsies." | 1.33 | Simultaneous, painless, homolateral oculomotor and trochlear nerve palsies in a patient with type 2 diabetes mellitus. Neuropathy or brainstem infarction? ( Heliopoulos, I; Maltezos, E; Papanas, N; Piperidou, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.35) | 18.7374 |
| 1990's | 2 (4.35) | 18.2507 |
| 2000's | 27 (58.70) | 29.6817 |
| 2010's | 15 (32.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capranzano, P | 3 |
| Capodanno, D | 3 |
| Fatima, N | 1 |
| Pingali, U | 1 |
| Muralidhar, N | 1 |
| Alexopoulos, D | 1 |
| Reed Chase, M | 1 |
| Friedman, HS | 1 |
| Navaratnam, P | 1 |
| Heithoff, K | 1 |
| Simpson, RJ | 1 |
| Carreras, ET | 1 |
| Hochholzer, W | 1 |
| Frelinger, AL | 2 |
| Nordio, F | 1 |
| O'Donoghue, ML | 1 |
| Wiviott, SD | 1 |
| Angiolillo, DJ | 10 |
| Michelson, AD | 2 |
| Sabatine, MS | 1 |
| Mega, JL | 1 |
| van Diepen, S | 1 |
| Fuster, V | 1 |
| Verma, S | 1 |
| Hamza, TH | 1 |
| Siami, FS | 1 |
| Goodman, SG | 1 |
| Farkouh, ME | 2 |
| Thott, O | 1 |
| Granath, F | 1 |
| Malmstedt, J | 1 |
| Wahlgren, CM | 1 |
| Goto, S | 1 |
| Aslam, M | 1 |
| Desai, B | 2 |
| Charlton, RK | 1 |
| Suzuki, Y | 1 |
| Box, LC | 1 |
| Shoemaker, SB | 1 |
| Zenni, MM | 1 |
| Guzman, LA | 1 |
| Bass, TA | 3 |
| de la Cruz, KI | 1 |
| Tsai, PI | 1 |
| Cohn, WE | 1 |
| Cooley, DA | 1 |
| Cerbone, AM | 1 |
| Macarone-Palmieri, N | 1 |
| Saldalamacchia, G | 1 |
| Coppola, A | 1 |
| Di Minno, G | 1 |
| Rivellese, AA | 1 |
| Merkely, B | 1 |
| Tóth-Zsamboki, E | 1 |
| Becker, D | 1 |
| Beres, BJ | 1 |
| Szabó, G | 1 |
| Vargova, K | 1 |
| Fülöp, G | 1 |
| Kerecsen, G | 1 |
| Preda, I | 1 |
| Spaulding, C | 1 |
| Kiss, RG | 1 |
| Singla, A | 1 |
| Antonino, MJ | 1 |
| Bliden, KP | 1 |
| Tantry, US | 1 |
| Gurbel, PA | 1 |
| Bernardo, E | 2 |
| Vivas, D | 1 |
| Sabaté, M | 3 |
| Ferreiro, JL | 3 |
| Ueno, M | 2 |
| Jimenez-Quevedo, P | 3 |
| Alfonso, F | 3 |
| Macaya, C | 3 |
| Fernandez-Ortiz, A | 2 |
| James, S | 1 |
| Cornel, JH | 1 |
| Erlinge, D | 1 |
| Husted, S | 1 |
| Kontny, F | 1 |
| Maya, J | 1 |
| Nicolau, JC | 1 |
| Spinar, J | 1 |
| Storey, RF | 1 |
| Stevens, SR | 1 |
| Wallentin, L | 1 |
| Radke, PW | 1 |
| Schunkert, H | 1 |
| Fu, Q | 1 |
| Yokoyama, N | 1 |
| Takada, K | 1 |
| Ishikawa, S | 1 |
| Isshiki, T | 1 |
| Badimon, JJ | 1 |
| Saucedo, JF | 1 |
| Jakubowski, JA | 1 |
| Zhu, B | 1 |
| Ojeh, CK | 1 |
| Baker, BA | 1 |
| Effron, MB | 1 |
| Dharmashankar, K | 1 |
| Darlington, A | 1 |
| Tello-Montoliu, A | 1 |
| Rollini, F | 1 |
| Dillinger, JG | 1 |
| Drissa, A | 1 |
| Sideris, G | 1 |
| Bal dit Sollier, C | 1 |
| Voicu, S | 1 |
| Manzo Silberman, S | 1 |
| Logeart, D | 1 |
| Drouet, L | 1 |
| Henry, P | 1 |
| Bhatt, DL | 2 |
| Marso, SP | 1 |
| Hirsch, AT | 1 |
| Ringleb, PA | 1 |
| Hacke, W | 1 |
| Topol, EJ | 2 |
| Mann, T | 1 |
| Cubeddu, RJ | 1 |
| Raynor, L | 1 |
| Bowen, J | 1 |
| Schneider, JE | 1 |
| Rose, G | 1 |
| Cubeddu, G | 1 |
| Raza, JA | 1 |
| Jobe, RL | 1 |
| Newman, W | 1 |
| Zellinger, M | 1 |
| Roffi, M | 1 |
| Malcolm, J | 2 |
| Meggison, H | 1 |
| Sigal, R | 2 |
| Mukherjee, D | 1 |
| Eikelboom, JW | 1 |
| Rankin, JM | 1 |
| Baumgartner, I | 1 |
| Brogan, GX | 1 |
| Peterson, ED | 1 |
| Mulgund, J | 1 |
| Ohman, EM | 1 |
| Gibler, WB | 1 |
| Pollack, CV | 1 |
| Roe, MT | 1 |
| Kirichenko, AA | 1 |
| Papanas, N | 1 |
| Heliopoulos, I | 1 |
| Piperidou, H | 1 |
| Maltezos, E | 1 |
| Ramírez, C | 1 |
| Costa, MA | 1 |
| Hernández, R | 1 |
| Moreno, R | 2 |
| Escaned, J | 2 |
| Bañuelos, C | 2 |
| Arnaout, A | 1 |
| Scheen, AJ | 1 |
| Legrand, D | 1 |
| Geisler, T | 1 |
| Anders, N | 1 |
| Paterok, M | 1 |
| Langer, H | 1 |
| Stellos, K | 1 |
| Lindemann, S | 1 |
| Herdeg, C | 1 |
| May, AE | 1 |
| Gawaz, M | 1 |
| Schäfer, A | 1 |
| Bonz, AW | 1 |
| Eigenthaler, M | 1 |
| Bauersachs, J | 1 |
| Hernández-Antolín, R | 1 |
| SanMartín, M | 1 |
| Gómez-Hospital, JA | 1 |
| Fernández, C | 1 |
| Fernández-Avilés, F | 1 |
| Serebruany, VL | 1 |
| Malinin, AI | 1 |
| Pokov, A | 1 |
| Barsness, G | 1 |
| Hanley, DF | 1 |
| Lee, SW | 1 |
| Park, SW | 1 |
| Kim, YH | 1 |
| Yun, SC | 1 |
| Park, DW | 1 |
| Lee, CW | 1 |
| Hong, MK | 1 |
| Kim, HS | 1 |
| Ko, JK | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Choi, SW | 1 |
| Seong, IW | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Kim, JH | 1 |
| Chun, KJ | 1 |
| Park, SJ | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Shapiro, LM | 1 |
| Cove, DH | 1 |
| Trethowan, N | 1 |
| Neumann, V | 1 |
| Mirouze, J | 1 |
| Nomura, S | 1 |
| Shouzu, A | 1 |
| Omoto, S | 1 |
| Nishikawa, M | 1 |
| Fukuhara, S | 1 |
| Nagai, T | 1 |
| Tomizawa, T | 1 |
| Tonooka, N | 1 |
| Mita, Y | 1 |
| Misumi, S | 1 |
| Mori, M | 1 |
| Hayakawa, M | 1 |
| Kuzuya, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56[NCT01235351] | Phase 2 | 335 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450] | Phase 3 | 1,900 participants (Actual) | Interventional | 2004-04-30 | Active, not recruiting | ||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.[NCT00642174] | Phase 2 | 35 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP. (NCT01235351)
Timeframe: Approximately every 2 weeks for 8 weeks
| Intervention | % of PRI (Mean) | |
|---|---|---|
| Clopidogrel 75 mg | Clopidogrel 150 mg | |
| CYP2C19*2 Non-Carriers | 57.5 | 46.9 |
The outcome measurement was on-treatment PRI determined through flow cytometric assessment of phosphorylation status of VASP. (NCT01235351)
Timeframe: Approximately every 2 weeks for 8 weeks
| Intervention | % of PRI (Mean) | |||
|---|---|---|---|---|
| Clopidogrel 75 mg | Clopidogrel 150 mg | Clopidogrel 225 mg | Clopidogrel 300 mg | |
| CYP2C19*2 Carriers | 71.0 | 62.4 | 54.0 | 50.1 |
median 3.8 years of follow-up (NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 26.6 |
| Coronary Artery Bypass Graft | 18.7 |
(NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.3 |
| Coronary Artery Bypass Graft | 10.9 |
(NCT00086450)
Timeframe: Measured at Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.8 |
| Coronary Artery Bypass Graft | 11.8 |
Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 4.8 |
| Coronary Artery Bypass Graft | 5.2 |
The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 4 hours after loading dose
| Intervention | percent inhibition (Least Squares Mean) | |
|---|---|---|
| Baseline | 4 Hours After Loading Dose | |
| Clopidogrel | 9.3 | 27.7 |
| Prasugrel | 9.4 | 89.3 |
Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 1 hour and 24 hours after the loading dose (LD) and 24 hours after the last maintenance dose (LMD)
| Intervention | percent inhibition (Least Squares Mean) | ||
|---|---|---|---|
| 1 Hour After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 13.4 | 29.3 | 44.2 |
| Prasugrel | 49.9 | 87.1 | 61.8 |
Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) - Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | millimeters (mm) (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 58.1 | 54.8 | 48.1 | 49.2 | 46.8 |
| Prasugrel | 56.8 | 38.5 | 24.2 | 29.3 | 44.2 |
Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent platelet aggregation (Least Squares Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (5 μM ADP) | 1 Hour After Loading Dose (5 μM ADP) | 4 Hours After Loading Dose (5 μM ADP) | 24 Hours After Loading Dose (5 μM ADP) | 24 Hours After Last Maintenance Dose (5 μM ADP) | Baseline (20 μM ADP) | 1 Hour After Loading Dose (20 μM ADP) | 4 Hours After Loading Dose (20 μM ADP) | 24 Hours After Loading Dose (20 μM ADP) | 24 Hours After Last Maintenance Dose (20 μM ADP) | |
| Clopidogrel | 65.7 | 56.7 | 44.6 | 45.6 | 38.3 | 76.9 | 69.8 | 57.5 | 58.4 | 50.7 |
| Prasugrel | 64.9 | 33.7 | 18.0 | 22.3 | 29.6 | 77.1 | 44.7 | 22.4 | 27.4 | 38.3 |
Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose
| Intervention | percent inhibition (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 1 Hour After Loading Dose | 4 Hours After Loading Dose | 24 Hours After Loading Dose | 24 Hours After Last Maintenance Dose | |
| Clopidogrel | 80.6 | 76.2 | 67.5 | 58.5 | 42.3 |
| Prasugrel | 83.5 | 40.0 | 14.5 | 15.7 | 27.4 |
11 reviews available for ticlopidine and Diabetic Angiopathies
| Article | Year |
|---|---|
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Diabetic Angiopat | 2013 |
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Huma | 2014 |
Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Arter | 2008 |
Diabetes, vascular complications and antiplatelet therapy: open problems.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Interactions; Drug Resistance; | 2009 |
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Ac | 2009 |
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease.
Topics: Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Ty | 2012 |
Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Corona | 2004 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Corona | 2003 |
Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients.
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Bypass; Diabetic Angiopathies; Humans; | 2005 |
[Mechanism of action and clinical use of ticlopidine].
Topics: Arterial Occlusive Diseases; Brain Ischemia; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Myo | 2006 |
Prevention of cardiovascular events in diabetes.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid | 2006 |
15 trials available for ticlopidine and Diabetic Angiopathies
| Article | Year |
|---|---|
Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fe | 2014 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Diabetes Mellitus, Type 2; Dia | 2016 |
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove | 2008 |
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Dia | 2010 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.
Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes | 2011 |
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies | 2013 |
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease.
Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over St | 2012 |
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus.
Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi | 2002 |
Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Clo | 2003 |
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death, | 2007 |
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
Topics: Adult; Analysis of Variance; Aspirin; Biomarkers; Blood Chemical Analysis; Clopidogrel; Diabetes Mel | 2008 |
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest | 2008 |
Clinical trials of an antiplatelet agent, ticlopidine, in diabetes mellitus.
Topics: Adult; Anticoagulants; Clinical Trials as Topic; Diabetic Angiopathies; Echocardiography; Female; Hu | 1983 |
Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
Topics: Adenosine Diphosphate; Adolescent; Adult; Aged; Anticoagulants; Brain Ischemia; Clinical Trials as T | 1984 |
Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group.
Topics: Adolescent; Adult; Aged; Diabetic Angiopathies; Diabetic Retinopathy; Diarrhea; Double-Blind Method; | 1990 |
20 other studies available for ticlopidine and Diabetic Angiopathies
| Article | Year |
|---|---|
Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2016 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The | 2017 |
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic | 2017 |
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh | 2009 |
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy.
Topics: Adult; Aged; Aspirin; Blood Glucose; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes | 2009 |
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe | 2010 |
Diabetics with acute coronary syndrome: advances, challenges, and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Diabetic Angiopathies; Humans; Purinergic P2Y Recep | 2010 |
Comparison of platelet P2Y(12) ADP receptor-mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP-phosphorylation in Japanese patients undergoing coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Blood Proteins; Cell Adhesion Molecules; Cilostazol; Clopidogr | 2010 |
Letter regarding article by Mehilli et al, "randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel".
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Protocols; Clopidogrel; | 2005 |
[In diabetes and peripheral arterial occlusive disease: long-term treatment with clopidogrel].
Topics: Arterial Occlusive Diseases; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Humans; L | 2005 |
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co | 2006 |
Simultaneous, painless, homolateral oculomotor and trochlear nerve palsies in a patient with type 2 diabetes mellitus. Neuropathy or brainstem infarction?
Topics: Aged; Cerebral Infarction; Clopidogrel; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic N | 2006 |
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.
Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug | 2006 |
Aspirin and clopidogrel resistance in patients with diabetes mellitus.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2006 |
Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.
Topics: Adenosine Diphosphate; Blood Platelets; Clopidogrel; Coronary Disease; Diabetic Angiopathies; Humans | 2007 |
Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely test platelet function?
Topics: Aged; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diabetic Angiopathies; Drug Resistance; Hu | 2007 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Significance of chemokines and activated platelets in patients with diabetes.
Topics: Adult; Annexin A5; Blood Platelets; Case-Control Studies; Chemokine CCL2; Chemokine CCL5; Chemokines | 2000 |
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia.
Topics: Aged; Aspirin; Cerebral Angiography; Cranial Sinuses; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2001 |
Effects of ticlopidine on erythrocyte aggregation in thrombotic disorders.
Topics: Aged; Diabetic Angiopathies; Dose-Response Relationship, Drug; Erythrocyte Aggregation; Female; Hexa | 1991 |